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Abstract
Background: HIV-1 viral protein Tat partially mediates the neural dysfunction and neuronal cell death associated with HIV-1
induced neurodegeneration and neurocognitive disorders. Soy isoflavones provide protection against various neurotoxic
insults to maintain neuronal function and thus help preserve neurocognitive capacity.
Methodology/Principal Findings: We demonstrate in primary cortical cell cultures that 17b-estradiol or isoflavones
(genistein or daidzein) attenuate Tat1–86-induced expression of apoptotic proteins and subsequent cell death. Exposure of
cultured neurons to the estrogen receptor antagonist ICI 182,780 abolished the anti-apoptotic actions of isoflavones. Use of
ERa or ERb specific antagonists determined the involvement of both ER isoforms in genistein and daidzein inhibition of
caspase activity; ERb selectively mediated downregulation of mitochondrial pro-apoptotic protein Bax. The findings suggest
soy isoflavones effectively diminished HIV-1 Tat-induced apoptotic signaling.
Conclusions/Significance: Collectively, our results suggest that soy isoflavones represent an adjunctive therapeutic option
with combination anti-retroviral therapy (cART) to preserve neuronal functioning and sustain neurocognitive abilities of HIV-
1 infected persons.
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Introduction
HIV-1 infection of the central nervous system (CNS) causes
several neurological disorders, known as HIV-associated neuro-
cognitive disorders (HAND) [1]. Although the incidence of severe
dementia has significantly decreased since the advent of combi-
nation anti-retroviral therapy (cART), cognitive and motor
impairments persist in up to 50% of HIV-1 positive patients due
to longer life expectancy, the lack of patient compliance with
cART therapy and the low penetrability of cART into the CNS
[2]. The continued prevalence of neurological dysfunction suggests
cART fails to provide complete protection from the development
of HAND [1,3,4] and there currently are no pharmacotherapies
targeted to HAND.
HIV-1 enters the brain early after infection and, although, HIV-
1 does not infect neurons, neuronal dysfunction is key in HIV
pathogenesis [5–7]. The early viral proteins such as Tat are
continually produced despite the presence of cART [7–10].
Accordingly, Tat is rapidly taken up by neuronal cells and has
been shown to have direct toxic effects on neurons though various
mechanisms. Studies have shown Tat to mediate excitotoxicity via
NMDA receptors [11–13], synaptic damage and dendritic pruning
[14], induce apoptotic cascades [15,16], calcium dysregulation
[17], oxidative stress [18], and dopaminergic system dysfunction
[19,20]. Tat exposure has been shown to negatively affect
cognitive processes in animal models [21,22]. The observations
that the viral regulatory protein Tat is actively secreted by infected
cells, and that Tat mRNA is elevated in patients with HIV-1
suggest a possible role of extracellular Tat in the progression of
HIV-1-induced neurodegeneration [23–25].
Phytoestrogens, such as the soy isoflavones genistein and
daidzein, mimic the neuroprotective actions and functions of
estrogen in the brain, as they bind to the estrogen receptor (ER)
and affect estrogen-mediated processes [26–29]. Several studies
have found that soy isoflavones can improve cognitive functions in
both humans and rats, but underlying mechanisms remain
unknown [30–35]. Additional studies have shown that isoflavones
have neuroprotective effects against various neurodegenerative
insults. Genistein and daidzein have demonstrated neuroprotective
efficacy against glutamate excitotoxicity and Ab25–35 induced loss
of cell viability, oxidative stress and initiation of apoptosis in
hippocampal neurons [36,37]. As the dopaminergic system is
sensitive to HIV in the brain, isoflavones, similar to estradiol, may
interact with dopamine to preserve motor and cognitive functions
[35,38–40].
Estrogen therapy is met with resistance due to its association
with reproductive and breast cancers [41,42]. However, dietary
consumption and supplementation with soy isoflavones is
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nanomolar concentrations of circulating isoflavones [43,44]. In
people consuming modest amount of soy products yielding
,50 mg/day of total isoflavones, plasma levels of 50–800 ng/ml
have been achieved for daidzein and genistein [43], which is
comparable to concentrations observed in a traditional Japanese
diet [44]. However, consuming a western vegetarian diet and
taking supplements has been shown to achieve increased
isoflavone consumption comparable to or higher than Asian
levels [44–46]. Furthermore, human studies that have reported
improved cognitive function with soy isoflavone consumption
have used ,60–100 mg/day doses of isoflavones [31,34]. The
cognitive improvements seen with high doses of soy in vivo were
not associated with abnormalities in reproductive health of
humans, including men [31,47–49]. This broadens the use and
benefits of these estrogenic compounds to not only women but
also men.
Soy isoflavones preferentially binding to ERb is of significant
consideration in neuroprotection as this ER subtype is highly
expressed in the brain compared to ERa, which due to its high
expression in the reproductive tissue, has been associated with the
proliferative effects of estrogen. Elucidating whether isoflavone
protection is mediated by ER selectivity is a central focus in
developing neuroprotective strategies. In the current experiments,
we investigated whether treatment with soy isoflavones, genistein
or daidzein, could attenuate HIV-1 Tat-induced mitochondria
associated apoptosis in cortical cell cultures. Further, we explored
whether isoflavone neuroprotection against HIV-1 viral protein
Tat-induced neural toxicity involves ER-mediated attenuation of
apoptotic signaling. We demonstrated that isoflavones maintained
neuronal cell viability in the presence of prolonged Tat exposure.
We also observed that isoflavones prevented Tat-induced
upregulation of mitochondrial apoptotic cascade regulators.
Moreover, we determined that the protective actions of isoflavones
were mediated by estrogen receptors.
Results
Physiological Doses of Genistein and Daidzein Prevent
Cell Death Following Tat1–86 Exposure
We have previously shown that 17b-estradiol attenuated Tat-
induced cell death [50]. As shown in Figure 1, the cell viability
decrease (<25% of control) induced by prolonged (up to 5 days)
exposure to the toxic dose of Tat1–86 B was abrogated by 0.1–
10 nM of 17b-estradiol. Similar alleviation of Tat-induced
neuronal cell death was observed when isoflavones GEN or
DAI were used at doses 0.05, 0.2, and 1 mM (Figure 1). Our
levels of 50 nM to 1.0 mM of genistein and daidzein are within
the range of observed plasma levels of isoflavones following
consumption of soy products which reflect ,200 nM-3 mM.
Results indicate that physiologically relevant concentrations of
isoflavones are able to effectively protect cortical neurons against
Tat toxicity in vitro.
Genistein and Daidzein Attenuate Tat-induced Caspase
Activation in Primary Cortical Cell Cultures
In the present experiments, we evaluated if the protective
potential of GEN and DAI against Tat involves downregulation of
caspase activity. Figure 2A shows significant caspase 9 activation
following only 4 hr of Tat exposure (p#0.05). Preincubation with
10 nM 17b-estradiol or 1 mM of isoflavones (GEN or DAI)
preventedtheincreaseinTat-inducedcaspase9activation.Cultures
pretreated with GEN or DAI displayed caspase 9 activity similar to
that of estradiol treated cultures (p#0.05). Moreover, analysis
revealedthatcaspase9activitywasnotstatisticallydifferentbetween
the 17b-estradiol, GEN and DAI pretreated cultures.
In regard to effector caspase 3 activity, a similar effect was
observed with phytoestrogen pretreatment prior to Tat exposure.
These results demonstrated a significant increase in caspase 3
activation in cortical cultures following 4 hr exposure to Tat
(p#0.05). The current experiments show that the addition of GEN
or DAI prior to incubation with 50 nM Tat significantly
attenuated the upregulation of active caspase 3 expression
(p#0.05, Figure 2B). The level of activation of caspase 3 in
GEN and DAI pretreatment groups was not significantly different
from that of vehicle-treated controls; furthermore, these levels
were very similar to that of the 17b-estradiol treated cultures.
These results indicate that isoflavones GEN and DAI downreg-
ulate Tat-induced caspase activation to a level comparable to that
of 17b-estradiol, suggesting that isoflavones and estradiol may
share a common neuroprotective mechanism.
Genistein and Daidzein Sustain Levels of Mitochondrial
Proteins Bax and Bcl-2 Expression Following Tat Exposure
The protection of cortical cell cultures with 17b-estradiol
against Tat toxicity is associated with regulating the effects of
apoptotic proteins linked to the mitochondrial apoptotic pathway
[50]. Therefore, we compared effects of neuroprotective concen-
trations of 17b-estradiol and isoflavones that completely eliminate
Tat-induced death of cortical cells on the alterations in Bcl-2 and
Bax protein levels. Results of the Bcl-2 ELISA presented in
Figure 3A demonstrate that, similar to estradiol (10 nM),
neuroprotective doses of GEN and DAI (1 mM) added to the cell
culture medium 24 hr in advance of 50 nM Tat significantly
(p#0.05) attenuated the increase of Bcl-2 expression; an effect
shown to occur within the first 16–24 hr of Tat exposure in
cortical cell cultures [50].
We also evaluated the efficacy of isoflavones against Tat-
induced Bax expression. Results of the Bax ELISA (Figure 3B)
demonstrate that pretreatment with 1 mM GEN or DAI, or
pretreatment with 10 nM estrogen, significantly (p#0.05) blocks
the induction of Bax expression in Tat-exposed cortical cells
(Figure 3B). Effects of all the compounds on Tat-induced changes
in Bcl-2/Bax protein expression were specific, since neither the
exposure to 10 nM 17b-estradiol, nor the exposure to 1 mM
isoflavones caused statistically significant changes in Bcl-2 or Bax
immunoreactivities compared to non-treated control cell cultures.
Estrogen Receptor Antagonists Block Anti-apoptotic
Actions of Soy Isoflavones
Plant isoflavones, such as GEN and DAI, are similar to 17b-
estradiol in chemical structure, which allows them to interact with
estrogen receptors (ER). Neuroprotective effects of 17b-estradiol
against Tat-induced apoptosis are mediated by two subtypes of
estrogen receptors, ERa and ERb. ER expression in primary
cortical neurons used in the current experiments demonstrates the
presence of both ER a and b immunoreactivity in our cultures
(data not shown). In the present experiments, we sought to
determine if the protective actions of isoflavones were ER-
mediated. The ER antagonist, ICI 182,780 (100 nM), was added
to cultures 1 hr prior to incubation with 17b-estradiol, GEN or
DAI. Following 24 hr pretreatment, 50 nM Tat was added to
cultures and its effects on the active caspase 3 (Figure 4A) and Bax
(Figure 4B) protein levels have been analyzed.
As shown in Figure 4A, ICI prevented the downregulation of
active caspase 3 by 17b-estradiol (10 nM), GEN or DAI (1 mM)
pretreatment. Consistent with our previous study, ICI 182,780
Isoflavones Reduce Tat-Induced Apoptosis
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of cortical cultures. Activated caspase 3 immunoreactivity in
ICI+GEN+Tat-treated cultures was significantly higher than
GEN+Tat treated cortical cultures (p#0.05) and protein levels of
activated caspase 3 were similar to that in Tat-only treated cultures.
Similarly, the DAI effects on caspase 3 were sensitive to ICI
inhibitionofERs.Therewasasignificantincreaseinactivecaspase3
expression with the addition of ICI compared to DAI+Tat treated
cultures(p#0.05).ResultsoftheexperimentsindicatethatGENand
DAI, similar to 17b-estradiol, inhibit the Tat-induced caspase 3
activation via an ER-mediated mechanism, as the addition of ICI
182,780priortoestradiolreturnedcaspase3activationlevelstothat
of Tat only treated cultures. Moreover, caspase 3 activity did not
differ statistically from that of Tat only treated cultures.
The results in Figure 4B show that GEN and DAI effects on Tat-
induced Bax expression in cortical cultures are ICI-sensitive. A
significant 25% increase in Bax expression was seen with ICI
treatmentpriortoincubationwithGENorDAI(p#0.05)(Figure4B).
Although,GENandDAIpossessestrogen-likeactivity,theiraffinity
toERa-orERb-subtypesissignificantlydifferentfrom17b-estradiol.
Therefore, we used specific antagonists of a or b ERs to evaluate
selectivity of the effects of 17b-estradiol, GEN and DAI on Tat-
inducedchangesinactivatedcaspase3orBaxproteinlevels.TheER-
subtype specific antagonists MPP (ERa) and PHTPP (ERb)( 1mM)
wereaddedtocorticalculturespriortoincubationwithGENorDAI
and subsequent exposure to 50 nMTat.
Neither a- nor b-selective ER antagonists were able to
completely block the inhibitory effects of 10 nM 17b-estradiol
Figure 1. Soy isoflavones genistein and daidzein protect primary cortical cultures from Tat neurotoxicity. Primary cortical neurons
were exposed to estrogen (0.1, 2.0 and 10 nM), or isoflavones (0.05, 0.2 and 1 mM) 24 hr prior to the start of Tat1–86 B (50 nM) treatment. Cell viability
was assessed by Live/Dead assay. Live/Dead ratios were determined after 48 hr (A-C) or 5 days (D-F) of the continuous exposure to Tat or equal
volume of vehicle in cell culture groups that were treated or not treated with estrogen, GEN, or DAI. Data represents mean values 6 SEM, n of
cultures analyzed =7–12 per each group. *- indicates significant (p#0.05) protective effects of the selected compounds against Tat neurotoxicity (cell
viability decrease) in cortical cell cultures. Repeated (2–3) trials using cell culture preparations from different litters were carried out to ensure the
reproducibility of the results.
doi:10.1371/journal.pone.0037540.g001
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caspase 3 activation (Figure 5B, C). Although the ER subtype
selective antagonists diminished the ability of all the compounds to
decrease active caspase 3 protein levels in Tat-treated cultures,
their effects were not statistically significant. Overall, selective
antagonists of ERa-o rE R b-subtypes similarly affected the ability
of both 17b-estradiol and isoflavones to downregulate Tat-induced
caspase 3 activation.
The addition of ERa antagonist MPP did not significantly
attenuate 17b-estradiol effects on Bax expression (Figure 5D), but
was able to significantly decrease the effect of GEN and DAI. The
ERb-specific antagonist PHTPP completely blocked the effect of
17b-estradiol and GEN (Figure 5E, F). PHTPP also caused a
partial, but significant, decrease in the ability of DAI to inhibit the
Tat-dependent increase in Bax expression.
Discussion
Neurocognitive deficits associated with HIV infection persist
even with effective cART [51]. Targeting ERb function may be a
potential therapeutic option since it is highly expressed in the
brain, specifically in cortical regions responsible for executive
functions significantly affected in HIV-1 associated neurocognitive
disorders (HAND) [35,52–54]. In this study, we evaluated whether
soy isoflavones, acting as ER selective compounds, were able to
mimic the neuroprotective effects of estrogen in HIV-1 Tat1–86-
exposed primary neuronal cultures. GEN and DAI represent soy
isoflavones with ERa/b binding profiles showing much higher
binding selectivity for ERb than 17b-estradiol. Among soy
phytoestrogens, GEN exhibits maximum ERa/b binding affinity
with approximately 60-fold preference for ERb over ERa. DAI
has lower ERa/b binding affinity than GEN with 14-fold
selectivity for ERb binding. For comparison with these two soy
isoflavones, 17b-estradiol’s preference for the ERb binding is 0.78-
fold [55]. GEN and DAI have very close chemical structures and
are known to induce neuroprotective responses but at a much
lower magnitude than 17b-estradiol.
Studies have demonstrated that oxidative stress and mitochon-
drial dysfunction coincide with Tat activation of apoptotic
cascades [16,38,50,56]. Moreover, we have recently reported that
17b-estradiol attenuated Tat-induced apoptotic signaling in an
estrogen-receptor dependent manner [50]. We now demonstrate
that the soy isoflavones genistein and daidzein prevent the
Figure 2. Genistein and daidzein attenuate Tat-induced
caspase activation in primary cortical cultures. Cortical cultures
were treated with 1 mM GEN or DAI 24 hr prior to Tat exposure.
Expression of activated apoptotic proteins A. Caspase 9 (4 hr of Tat
exposure) and B. caspase 3 (4 hr Tat exposure) was assessed by ELISA
experiments. Data represents mean values 6 SEM, with experiments
performed in triplicate, *p#0.05 as compared to Tat-treated cultures.
doi:10.1371/journal.pone.0037540.g002
Figure 3. Isoflavones prevent Tat-induced expression of Bcl-2
and Bax protein levels. Cortical cultures were treated with 1 mM GEN
or DAI 24 hr prior to Tat exposure. Expression of apoptotic proteins A.
Bcl-2 (16 hr of Tat exposure) and B. Bax (4 hr Tat exposure) were
assessed by ELISA experiments. Data represents mean values 6 SEM,
with experiments performed in triplicate, *p#0.05 as compared to Tat-
treated cultures.
doi:10.1371/journal.pone.0037540.g003
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addition, upstream of caspase activation, we show that Tat
exposure significantly increased expression of pro- and anti-
apoptotic proteins Bax and Bcl-2 respectively, which regulate
mitochondrial membrane permeability and thus, the release of
apoptogenic substances. Our results indicate that treatment with
GEN or DAI also markedly reduces the expression of Bax and Bcl-
2 in Tat-exposed cortical cultures. A major finding of our study is
that both soy isoflavones GEN and DAI exhibited protective
effects similar to that exhibited by 17b-estradiol. GEN and DAI
increased cell viability and attenuated the upregulation of
apoptotic proteins in a manner comparable to that observed in
estradiol treated cultures. At low micromolar doses we observed
that isoflavones were able to maintain cell survival following
prolonged exposure to Tat. These results suggested a similar
neuroprotective action of isoflavones and 17b-estradiol involving
inhibition of apoptotic pathways. Our experiments also demon-
strated that selective ERb agonists induce an anti-apoptotic effect
in primary cultures exposed to HIV-1 Tat. Such observations
support the findings that isoflavones are protective against
oxidative stress-mediated apoptosis in HIV-1 infection.
Since isoflavones bind estrogen receptors (ERs), the neuropro-
tective actions of isoflavones may be produced through activation
of the ER. We found that the addition of the ER antagonist ICI
182,780, which blocks both the ERa and ERb subtypes, reversed
GEN and DAI downregulation of caspase 3 activity and Bax
expression with Tat exposure, suggesting that these effects of GEN
and DAI were ER-dependent. The addition of ICI 182,780 had a
more robust effect against genistein actions on caspase 3 activity,
and sustained caspase levels similar to cultures treated with Tat.
Furthermore, an isoflavone effect on Bax expression was also
shown to be ER-dependent, as ICI 182,780 blocked genistein and
daidzein inhibition of Tat-induced Bax expression. Collectively,
our results suggest that genistein and daidzein act as estrogen
receptor agonists in primary cortical neurons and activate
estrogenic neural defense mechanisms.
Another major finding is that isoflavone anti-apoptotic effects
are selective relative to estrogen receptor isoform. There are
conflicting reports of which ER subtype, ERa or ERb, specifically
mediates the protective actions of estrogen [57,58]. We observed
in our previous studies with estradiol [50], inhibition of ERs with
ICI 182,780 blocked the downregulation of apoptotic proteins in
cultures pretreated with isoflavones. Further experiments sought to
determine if these receptor-mediated effects were specific to a
particular ER-subtype. Cultures in the presence of ERa-specific
antagonist MPP or ERb-specific antagonist PHTPP did not show
specific attenuation of genistein and daidzein downregulation of
caspase 3 activity. Similar to previous results observed with
estradiol, both ER subtypes seem to play a role in genistein and
daidzein inhibition of Tat activation of caspase 3. However, a
more pronounced attenuation of genistein effects on Bax
expression was observed in the presence of ERb antagonist
PHTPP. Thus, genistein effects on Bax expression may be
preferential for ERb-mediated signaling. Our results also demon-
strated that the addition of both ER subtype antagonists
significantly inhibited daidzein actions on Bax expression,
suggesting involvement of both ERa and ERb in daidzein
downregulation of Bax. It is possible that daidzein’s lower binding
affinity for ERs compared to that of genistein and estradiol [55]
may explain the absence of the preferential mediation of a specific
ER subtype. Another point of consideration is that ERa and ERb
may act simultaneously and thus counteract the function of the
other receptor subtype [59,60]. Both genistein and daidzein were
shown to activate binding to ERb at nanomolar concentrations
(30 nM and 350 nM, respectively), which are easily achievable
levels in humans consuming soy products or supplements. At the
concentrations used in these experiments, it is plausible that both
receptor subtypes were activated and as such ER subtype specific
effects may be diminished.
Caspase 3 has a pivotal role in the apoptotic process.
Multiple pro-apoptotic pathways converge on caspase 3
activation in the cell death cascade. Caspase 3 activation may
occur through caspase 9 from the mitochondria or from death
receptor signaling via caspase 8 as well as through other pro-
apoptotic pathways [61–63]. More upstream in the apoptotic
cascade, the upregulation of Bax is associated with mitochon-
drial membrane permeabilization and release of pro-apoptotic
factors from mitochondria, leading to caspase activation. The
ERb specific effects on Bax may be related to the recent
discovery of ERb localization in mitochondria [64], suggesting a
direct estrogenic effect on mitochondria function via ERb
activation and signaling. The ER-mediated reduction of caspase
3 activity and Bax expression by estradiol and isoflavones
suggested that these compounds disrupt apoptotic signaling by
downregulating key pro-apoptotic factors in the cell death
cascade. As multiple apoptotic pathways converge on mito-
chondria functioning and caspase 3 activation, Bax and caspase
3 represent potential upstream and downstream receptor-
sensitive check points for estrogenic compounds to disrupt
apoptotic processing in response to neurodegenerative insults.
As isoflavones affect the viability of neurons and cognitive
function by acting as an estrogenic agonist, they can also utilize
differential distribution and regulation of the ER subtypes, ERa
Figure 4. Estrogen receptors mediate isoflavone effects on
Caspase 3 and Bax expression following Tat exposure. A. GEN
or DAI effects on caspase 3 expression were blocked in the presence of
ER antagonist, ICI 182,780. B. GEN or DAI effects on Tat-induced
expression of Bax were reversed by ICI 182,780, suggesting that
estrogenic actions on caspase 3 and Bax are ER mediated. Data
represents mean values 6 SEM, *p#0.05 vs. GEN/DAI+T treated
cultures.
doi:10.1371/journal.pone.0037540.g004
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ERa and ERb regulate different genes [65,66]. Differences in
conformation that occur upon ER binding affects the recruit-
ment of coregulatory proteins, and thus produces differential
gene regulation in specific cell types. In addition to tissue or
region specific localization of ERs, intracellular localization of
ERs may contribute to some of their different mechanisms of
action. ERb has been localized to a greater extent at
extranuclear sites and in the cytoplasm for trafficking to the
plasma membrane [64,67,68]. The extranuclear and membrane
localization of ERb enables its interaction with intracellular
signaling cascades to integrate rapid signaling events and
classical transcriptional mechanisms [69,70]. Given the timing
of treatment in our studies, both genomic and nongenomic
molecular actions may be utilized by isoflavones to confer ER-
mediated neuroprotection against Tat.
Despite the success of cART on peripheral viral suppression,
protected viral reservoirs in the brain may allow continued
release and exposure to toxic viral proteins [10]. The inability of
anti-retroviral therapy to prevent the development of neurocog-
nitive dysfunction indicates the need for adjunctive therapies to
address the neurodegenerative and subsequent neurological
disturbances associated with HAND. Findings in the present
study demonstrate that soy isoflavones offer a similar protective
effect as endogenous estradiol via a selective estrogen receptor -
mediated mechanism against HIV-1 Tat-induced cell death.
Isoflavones, acting as selective ER agonists targeting the
neuroprotective effects associated with estradiol, may represent
a safe and viable neuroprotectant along with cART to improve
the neurological health of both men and women with HAND.
Materials and Methods
Ethics Statement
All of the experimental procedures using animals were
performed in accordance with the recommendations in the NIH
Guide for the Care and Use of Laboratory Animals. The relevant
animal use protocols were approved by the University of South
Carolina Animal Care and Use Committee under the auspices of
Animal Assurance Number A3049-01.
Primary Neuronal Cell Culture
Primary cultured cortical neurons were prepared from 18-day-
old Sprague-Dawley rat fetuses [50]. Rat cortices were dissected
and incubated for 15 min in a solution of 2 mg/mL trypsin in
Ca
2+- and Mg
2+-free Hanks’ balanced salt solution (HBSS)
Figure 5. ER subtype specific effects against caspase activity and Bax expression. Similar to 17b-estradiol (A), GEN (B) and DAI (C) effects
against Tat-induced caspase 3 activity were maintained in the presence of specific antagonists for ERa (MPP) and ERb (PHTPP). ER subtype
antagonists reveal that ERb signaling was preferential for GEN (E) effects on Bax. DAI (F) effects on Bax were blocked in the presence of both ER
subtype antagonists. Data represents mean values 6 SEM, *p#0.05 as compared to GEN/DAI+Tat treated cultures.
doi:10.1371/journal.pone.0037540.g005
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tissue was then exposed for 2 min to soybean trypsin inhibitor
(1 mg/mL, in HBSS) and then rinsed 3 times in HBSS. Cells were
dissociated by trituration and distributed to poly-L-lysine coated
culture plates with wells containing DMEM/F12 medium (Invitro-
gen) supplemented with 100 mL/L fetal bovine serum (Sigma
Chemicals, St. Louis, MO). After a 24-hr period, the DMEM/F12
medium was replaced with 2% v/v B-27 Neurobasal medium
supplemented with 2 mM GlutaMAX and 0.5% w/v D-(+) glucose
(Invitrogen). Two-thirds of the neurobasal medium was replaced
with fresh medium of the same composition once a week. Cultures
were used for experiments after 12 days in culture in serum-free
medium and were .95% neuronal as observed by anti-MAP-2
immunostaining.
Tat1–86 Exposure and Experimental Treatment of Cultures
Recombinant Tat1–86 (LAI/Bru strain of HIV-1 clade B,
GenBank accession no. K02013, Diatheva, Fano, Italy) was added
to cell culture medium. Groups of cultures in 24-well plates were
exposed to 50 nM Tat. Cell cultures were treated with 17b-
estradiol (0.1 nM, 2 nM or10 nM, Sigma) or soy isoflavones
(0.05 mM, 0.2 mM or1 mM, genistein (GEN) or daidzein (DAI),
Indofine Chemical) for 24 hr prior to Tat exposure and remained
present in medium throughout experiments. 17b-estradiol was
dissolved in sterile water and diluted in D-PBS. Isoflavones were
dissolved in DMSO and diluted in D-PBS. To assess neurotoxicity,
the cultures were exposed to Tat for 4, 16, or 24 hr before
harvesting. After treatment, medium was removed, cells were
washed and lysates collected for ELISA experiments. Cells were
also treated with the estrogen receptor antagonist ICI 182,780, the
ERa specific antagonist, MPP dihydrocloride, or the ERb specific
antagonist PHTPP (100 nM, Tocris Cookson Inc, Ellisville, MO)
1 hr before estradiol or isoflavone treatment to determine if the
effects against Tat toxicity were receptor mediated.
Cell Viability Assay
Neuronal survival was determined using a Live/Dead viability/
cytotoxicity kit (Molecular Probes, Eugene, OR) in rat fetal
cortical cell cultures prepared in 96-well plates. In accordance with
the manufacturer’s protocol, neurons were exposed to cell-
permeate calcein AM (2 mM), which is hydrolyzed by intracellular
esterases, and to ethidium homodimer-1 (4 mM), which binds to
nucleic acids. The cleavage product of calcein AM produces a
green fluorescence (F530 nm) when exposed to 494-nm light and is
used to identify live cells. Bound ethidium homodimer-1 produces
a red fluorescence (F645 nm) when exposed to 528-nm light,
allowing the identification of dead cells. Fluorescence was
measured using a Bio-Tek Synergy HT microplate reader (Bio-
Tek Instruments, Inc., Winooski, VT). Each individual F530 nm
and F645 nm value on a plate was corrected for background
fluorescence (readings obtained from cell cultures (wells) that were
not exposed to calcein AM and ethidium bromide) by the
microplate reader KC4 software package (Bio-Tek Instruments,
Inc., Winooski, VT). For each individual cell culture (well) on a
plate, ratios between corrected green and red fluorescence (F530
nm/F645 nm, Live/Dead ratios) were calculated. All individual
relative numbers of live and dead cells were expressed in terms of
percentages of average maximum Live/Dead ratio determined for
the set of non-treated control cell cultures (8–16 wells) from the
same plate: (F530 nm/F645 nm)well n/(F530 nm/F645 nm)average max 6
100%.
Detection of Apoptotic Proteins (ELISA)
Expression of apoptotic signaling proteins in cell lysates was
determined by ELISA [16,50]. Cell lysates were prepared from
cultures grown in 24-well plates. At the time of harvesting,
medium was removed and cells were washed 3 times with
Dulbecco phosphate-buffered saline, D-PBS, (8 mM Na2HPO4,
1.5 mM KH2PO4, 0.137 M NaCl and 2.7 mM KCL at pH 7.4)
and lysed with CellLytic
TM- M mammalian cell lysis buffer (Sigma
Chemicals) containing protease inhibitors (protease inhibitors
cocktail, Sigma Chemicals). All samples in a group (6 culture
wells) were pooled together and protein concentration was
determined by the BCA method (Pierce, Rockford, Ill.). Each
well of Costar 96-well ELISA plates (Corning Inc, PA) was coated
overnight at 4uC using 100 mL of 20 mM carbonate coating
buffer, pH 9.6. Cortical cell lysate samples were diluted 1:10 with
D-PBS and 20 mg of each sample were added to the plate wells.
After overnight incubation at 4uC, plates were rinsed 5 times with
PBST (0.05% Tween 20 in PBS, pH 7.4) and blocked with 1%
BSA in PBS for 2 hr at room temperature. After blocking, plates
were washed again, as described above, and primary anti-Bax,
anti-Bcl-2, anti- active Caspase 9 and anti- active Caspase 3
antibodies (all primary antibodies, Abcam, Cambridge, MA)
diluted 1:5000 or 1:7500 (caspase 3) in 0.1% BSA-PBST were
added to each well except for blanks and no-primary antibody
control wells. Plates were kept overnight at 4uC. When the
incubation with primary antibodies was completed, plates were
again washed 5 times with PBST and secondary antibodies [goat
anti-rabbit alkaline phosphatase conjugated, Sigma] diluted
1:2000 in 0.1% BSA-PBST were added to each well, except for
blank and no-secondary antibody control wells. After 2 hr of
incubation, the secondary antibody solution was removed, plates
were washed 5 times with PBST and 100 mL of BluePhos
phosphatase substrate mixture (KPL Research, Gaithersburg,
MD) was added to the plate wells. After 30 min of incubation, the
absorbance at 650 nm was determined using a Bio-Tek Synergy
HT microplate reader. Multiple readings were taken within a 1-hr
time period.
Statistical Analysis
Statistical comparisons were made using one-way ANOVA and
Tukey’s multiple comparison tests were used to determine specific
treatment effects. Significant differences were set at p#0.05. Data
represents mean values 6 standard error of the mean (SEM).
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